New Unit To Leverage In-House Data and Provide “Science to Succeed”
LAS VEGAS, Feb. 5, 2018 /PRNewswire/ — Digipath, Inc. (OTCQB: DIGP), a service-oriented independent testing laboratory, data and media firm focused on the developing cannabis and hemp market, is pleased to announce the launch of “GroSciences.” GroSciences, a subsidiary of Digipath, has been established in Colorado to accelerate product development and increase quality for companies who wish to participate in the ever-expanding cannabis marketplace.
Since its inception, Digipath has collected data on every cannabis sample it has tested. The result is a dynamic, expanding and well-defined understanding of the science of cannabis and its practical application in all phases of product development. With leading cannabis scientist, Dr. Cindy Orser, overseeing the Company’s science and technology, Digipath is now prepared to provide aspiring cannabis producers the “Science to Succeed.”
“New ideas abound in the exploding cannabis market. Inventors and product strategists are creating cannabis-inspired product offerings in personal care, cosmetics, OTC and the horticultural market using this amazing plant,” stated Todd Denkin, President and CEO, Digipath, Inc. “Unfortunately, many of these great ideas lack the fundamental understanding and science to deliver formulations that can sustain itself in an increasingly competitive market.”
Dr. Cindy Orser, Chief Science Officer of Digipath, Inc. added, “GroSciences will provide private-label producers with the formulations and recipes to pursue real-world success. Our formulations are science-backed creations derived from years of testing cannabis and cannabis-based products at one of the most respected labs in the world. GroSciences will provide a new approach to product development and human wellness with new cannabis-based opportunities.”
About Digipath, Inc. &Digipath Labs, Inc.
Digipath, Inc. supports the cannabis industry’s best practices for reliable testing, data acquisition, cannabis education and training, and brings unbiased cannabis news coverage to the cannabis industry. Digipath Labs provides pharmaceutical-grade analysis and testing to the cannabis industry to ensure producers, consumers, and patients know exactly what is in the cannabis they ingest and to help maximize the quality of its client’s products through analysis, research, development, and standardization.
Digipath Investor Relations & Financial Media
info@integrityir.com
Toll Free: (888) 216-3595
www.IntegrityIR.com
Information about Forward-Looking Statements
This press release contains “forward-looking statements” that include information relating to future events. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in, or suggested by, the forward-looking statements. Important factors that could cause these differences include, but are not limited to: the Company’s need for additional funding, the demand for the Company’s products, governmental regulation of the cannabis industry, the Company’s ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, growth in targeted markets, the adequacy of the Company’s liquidity and financial strength to support its growth, and other risks that may be detailed from time-to-time in the Company’s filings with the United States Securities and Exchange Commission. For a more detailed description of the risk factors and uncertainties affecting Digipath, please refer to the Company’s recent Securities and Exchange Commission filings, which are available at www.sec.gov. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
SOURCE Digipath, Inc.
